About Beyondspring Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.beyondspringpharma.com/en/
Frequently Asked Questions
What is the 52-week range for BYSI?
The 52-week high is $2.44 and the 52-week low is $0.5657.
What is the P/E ratio for BYSI?
The P/E ratio data is currently unavailable.
What is the dividend yield for BYSI?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -133.13%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -4750.48%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 6.64.
Analyst Recommendation Trends
Wall Street analyst consensus for BYSI over the last few months:
Latest BYSI News
Top movers analysis one hour before the close of the markets on 2026-09-29: top gainers and losers in today's session.
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC Transcript
BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC September 29, 2026...
BeyondSpring Secures FDA Fast Track Designation for Plinabulin as DUBLIN-4 Phase 3 Trial Advances
BeyondSpring received FDA Fast Track designation for Plinabulin plus docetaxel in post-ICI non-squamous NSCLC and announced a strategic transaction designed to reduce the cash required to advance its global Phase 3 DUBLIN-4 trial toward a prespecified interim analysis. Key Investor TakeawaysBeyondSpring (NASDAQ:BYSI) received FDA Fast Track designation for Plinabulin plus docetaxel in advanced or metastatic non-squamous NSCLC following prior anti-PD-(L)1 therapy and platinum chemotherapy.
Traders are paying attention to the gapping stocks in Tuesday's session.
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Stablecoin Development (AMEX:SDEV) stock increased by 121.6% to $3.48 during Tuesday's regular session. The market value of their outstanding shares is at $42.5 million. Iovance Biotherapeutics
These stocks that are showing activity before the opening bell on Tuesday.
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
FDA Fast Track designation represents an important regulatory milestone for the Plinabulin and docetaxel combination as an anticancer regimen in 2L/3L advanced or metastatic non-squamous NSCLC without actionable genomic alterations (AGAs) following progression on immune checkpoint inhibitor (ICI) and chemotherapy.BeyondSpring enters into a strategic transaction to sell its majority equity interest in its Chinese subsidiary to an investor who will fund the China portion of the Phase 3 DUBLIN-4 tr
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock rose 16.34%
Monday's after hours session: top gainers and losers
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. Chemomab Therapeutics (NASDAQ:CMMB)
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Greenland Mines (NASDAQ:GRML) stock rose 108.1% to $5.93 during Monday's pre-market session. The market value of their outstanding shares is at $9.0 million. Cue Biopharma (NASDAQ:CUE) stock moved upwards
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 76.4% to $4.3 during Thursday's regular session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma (AMEX:AEON) shares
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-01 | Majeti Jiangwen | +100,000 | - | - |
| 2026-07-01 | Qiu Min | +100,000 | - | - |
| 2026-04-01 | Kirkby Matthew | +23,902 | - | - |
| 2026-04-01 | Delaney Brendan | +20,427 | - | - |
| 2026-04-01 | Majeti Jiangwen | +21,730 | - | - |
| 2026-04-01 | Lu Yingjuan June | +17,840 | - | - |
| 2026-04-01 | Huang Lan | +11,514 | - | - |
| 2026-04-01 | Xu Sihai | +18,689 | - | - |
| 2026-04-01 | Fabbio Patrick | +22,165 | - | - |
| 2026-03-20 | Huang Lan | -260,582 | - | - |
| 2025-10-17 | Cui Xiangmin | -45,513 | $1.76 | $80,103 |
| 2025-10-16 | Cui Xiangmin | -85,798 | $1.72 | $147,573 |
| 2025-10-15 | Cui Xiangmin | -17,960 | $1.65 | $29,634 |
| 2025-10-14 | Cui Xiangmin | -28,495 | $1.65 | $47,017 |
| 2025-10-13 | Cui Xiangmin | -107,361 | $1.7 | $182,514 |
| 2025-10-10 | Cui Xiangmin | -2,390 | $1.77 | $4,230 |
| 2025-10-09 | Cui Xiangmin | -3,979 | $1.81 | $7,202 |
| 2025-10-08 | Cui Xiangmin | -7,507 | $1.77 | $13,287 |
| 2025-10-07 | Cui Xiangmin | -2,100 | $1.79 | $3,759 |
| 2025-10-06 | Cui Xiangmin | -17,500 | $1.78 | $31,150 |